Cancer Research Institute   Report issue

Foundation Phase 1 Phase 2
Founded: New York NY United States (1953)

Organization Overview

First Clinical Trial
2005
NCT00124124
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cancer Research Institute, New York City

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Appendiceal Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Glioblastoma (Phase 2)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Second Primary (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Testicular Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 20
  • # of Trial APIs: 30